News and Events

February 23, 2022 11 am EST

Registration Open "Defining Specificity within the ELISpot Assay" Presented by TJ Beadnell, PhD, Scientific Manager, R&D. 

January 25-27, 2022

Eurofins Viracor BioPharma will be attending at the DDR 5th Annual PARP, ATR & DDR Inhibitors Summit which is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications. 

VIEW ON DEMAND  "Viral shedding and infectivity testing in clinical trials of Oncolytic virotherapy" presented by Kristen Mickey, Research Scientist, R&D. 

Check out the latest BioPharma Newsletter featuring how Eurofins Viracor targets precision oncology with the launch of PanCancer IQ™ and learn about new services and analytical techniques, research projects and other related topics. 

Eurofins Viracor BioPharma is proud to announce that we will be opening a state-of-the art, 110,000 sq. ft testing facility, nearly doubling our footprint in 2022.

27 Sep- 1 Oct 2021

Eurofins will be attending the 15th WRIB and excited to share how our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs — together with testing performed in our high throughput CAP/CLIA laboratory can advance your study design and clinical trial program.

30 Nov- 2 Dec 2021

Eurofins Viracor BioPharma will be exhibiting and sponsoring the World Vaccine and Immunotherapy Congress and we are excited to share our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs.

26-28 Oct 2021

Eurofins Viracor BioPharma will be exhibiting and sponsoring the 6th Annual Oncolytic Virotherapy Summit in Boston, October 26-28th, and we are excited to share our latest comprehensive assay offering for next generation sequencing to enable genomic profiling of tumor samples with PanCancerIQ™. Kristen Mickey will be presenting on October 28th "Viral shedding and infectivity testing in clinical trials of oncolytic virotherapies".

It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.

Check out the latest BioPharma Newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.